June 13, 2025
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
AMA resolution calls for broader access to GLP-1 medications
The AMA passed a resolution to increase access to anti-obesity medications at its annual House of Delegates meeting.The resolution was championed by the Endocrine Society, according to a press release, and builds upon existing AMA policy that advocates for improved access to other obesity treatments, like bariatric surgery.
TL;DRAI
AMA expands GLP-1 access by cutting prior authorization and insurer barriers—15–20% weight loss proven, yet <20% employers cover and Medicare excluded. Signals shift in healthcare strategy: removing prescriptive friction on effective anti-obesity drugs reduces $173B annual obesity costs, reshaping employer benefits.
741 words~3 min read
